🧫 In an interview, experts from Cytiva discuss the trends and challenges in the cell and gene therapy industry.
🔬 Gene therapy is seeing a rise in gene editing therapeutics, but cost and access remain challenges.
💉 The FDA is working on accelerating approval processes and improving manufacturing practices.
📈 Autologous CAR-T cell therapies are moving to earlier treatment stages, while allogeneic cell therapies and solid tumor therapies are being developed.
🤖 Greater adoption of automation and digital solutions is necessary to accelerate the manufacture and adoption of cell therapies.
💼 Collaboration and flexible regulatory pathways are key to advancing the industry and delivering therapies to patients.
💪 Industry collaborations between companies like Cytiva-Bayer and AstraZeneca-Oxford University are driving innovation in cell and gene therapy manufacturing.
Introduction:
The global cell and gene therapy market is expected to experience significant growth in the coming years. Experts at Cytiva predict several trends in the industry, including the rise of gene editing therapeutics, the need for improved manufacturing practices, and the push for standardization and industrialization of the manufacturing process. Additionally, the development of allogeneic cell therapies and therapies for solid tumors are expected to continue. The industry also faces challenges such as scale-up and industrialization of processes, understanding the body’s response to in vivo viral vectors, and the adoption of automation and digital solutions. Collaboration and regulatory flexibility are essential for the industry to move forward and deliver innovative therapies to patients.
- The gene therapy industry is seeing a rise in gene editing therapeutics and the need for improved manufacturing practices.
- The development of allogeneic cell therapies and therapies for solid tumors is expected to continue.
- The industry faces challenges in scale-up and industrialization of processes, understanding the body’s response to viral vectors, and adoption of automation and digital solutions.
- Collaboration and regulatory flexibility are crucial for the industry to accelerate development and deliver therapies to patients.
Conclusion:
The cell and gene therapy industry is experiencing significant growth, with several trends expected in the coming years. However, challenges such as manufacturing practices, understanding the body’s response to viral vectors, and adoption of automation and digital solutions need to be addressed. Collaboration and regulatory flexibility are essential for the industry to overcome these challenges and deliver innovative therapies to patients.
